Successful tocilizumab therapy in seven patients with refractory adult-onset Still's disease

被引：29

作者：

Bannai, Ei ^{[1
]}

Yamashita, Hiroyuki ^{[1
]}

Kaneko, Shunta ^{[1
]}

Ueda, Yo ^{[1
]}

Ozaki, Takashi ^{[1
]}

Tsuchiya, Haruka ^{[1
]}

Takahashi, Yuko ^{[1
]}

Kaneko, Hiroshi ^{[1
]}

Kano, Toshikazu ^{[1
]}

Mimori, Akio ^{[1
]}

机构：

[1] Natl Ctr Global Hlth & Med, Div Rheumat Dis, Shinjuku Ku, 1-21-1 Toyama, Tokyo 1628655, Japan

来源：

MODERN RHEUMATOLOGY | 2016年 / 26卷 / 02期

关键词：

Adult-onset Still's disease; Tocilizumab; Macrophage activation syndrome; MACROPHAGE ACTIVATION SYNDROME; TUMOR-NECROSIS-FACTOR; RHEUMATOID-ARTHRITIS; RECEPTOR ANTIBODY; IL-6; RECEPTOR; EFFICACY; INTERLEUKIN-6; AGENTS; TRIAL;

D O I：

10.3109/14397595.2014.899178

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

To evaluate the effects of tocilizumab (TCZ) on adult-onset Still's disease (AOSD), we reviewed medical records of seven patients with refractory AOSD treated with TCZ at our institution. TCZ therapy might allow rapid corticosteroid tapering and help maintain remission status, that is, resolution of clinical symptoms and normalization of biomarkers such as CRP and ferritin. Patients, however, should be monitored for the development of macrophage activation syndrome when TCZ is administered for active AOSD.

引用

页码：297 / 301

页数：5

共 50 条

[41] Adult-onset Still's disease: Advances in the treatment
Castaneda, Santos
Blanco, Ricardo
Gonzalez-Gay, Miguel A.
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 2016, 30 (02): : 222 - 238
[42] Rescued from desperation: adult-onset Still's disease with life-threatening interstitial lung disease and macrophage activation Successful treatment by Tocilizumab
Zhang, Guangfeng
Liu, Wenxue
Zhang, Xiao
Liu, Liang
ZEITSCHRIFT FUR RHEUMATOLOGIE, 2022, 81 (04): : 335 - 338
[43] A case of refractory adult-onset Still's disease successfully controlled with tocilizumab and a review of the literature
Perdan-Pirkmajer, Katja
Praprotnik, Sonja
Tomsic, Matija
CLINICAL RHEUMATOLOGY, 2010, 29 (12) : 1465 - 1467
[44] Glucocorticoid and cyclosporine refractory adult onset Still’s disease successfully treated with tocilizumab
Kazuko Matsumoto
Takao Nagashima
Shino Takatori
Yuta Kawahara
Masaki Yagi
Masahiro Iwamoto
Hitoaki Okazaki
Seiji Minota
Clinical Rheumatology, 2009, 28 : 485 - 487
[45] Clarithromycin in Adult-Onset Still's Disease A Potentially Useful Therapeutic
Thanou-Stavraki, Aikaterini
Aberle, Teresa
Aksentijevich, Ivona
Bane, Barbara L.
Harley, John B.
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2011, 17 (07) : 373 - 376
[46] Pathophysiology, subtypes, and treatments of adult-onset Still's disease: An update
Gerfaud-Valentin, M.
Seve, P.
Hot, A.
Broussolle, C.
Jamilloux, Y.
REVUE DE MEDECINE INTERNE, 2015, 36 (05): : 319 - 327
[47] A case of refractory adult-onset Still’s disease successfully controlled with tocilizumab and a review of the literature
Katja Perdan-Pirkmajer
Sonja Praprotnik
Matija Tomšič
Clinical Rheumatology, 2010, 29 : 1465 - 1467
[48] Etanercept-refractory adult-onset Still’s disease with thrombotic thrombocytopenic purpura successfully treated with tocilizumab
Keiichi Sumida
Yoshifumi Ubara
Junichi Hoshino
Tatsuya Suwabe
Rikako Hiramatsu
Eiko Hasegawa
Noriko Hayami
Masayuki Yamanouchi
Naoki Sawa
Fumi Takemoto
Kenmei Takaichi
Clinical Rheumatology, 2010, 29 : 1191 - 1194
[49] Successful tocilizumab treatment in a patient with adult-onset Still's disease complicated by chronic active hepatitis B and amyloid A amyloidosis
Kishida, Dai
Okuda, Yasuaki
Onishi, Makoto
Takebayashi, Masashi
Matoba, Kenichiro
Jouyama, Kazuo
Yamada, Akihiro
Sawada, Naoya
Mokuda, Sho
Takasugi, Kiyoshi
MODERN RHEUMATOLOGY, 2011, 21 (02) : 215 - 218
[50] The effectiveness of tocilizumab in treating refractory adult-onset Still's disease with dichotomous phenotypes: IL-18 is a potential predictor of therapeutic response
Tang, Kuo-Tung
Hsieh, Chia-Wei
Chen, Hsin-Hua
Chen, Yi-Ming
Chang, Shih-Hsin
Huang, Po-Hao
Lan, Joung-Liang
Chen, Der-Yuan
CLINICAL RHEUMATOLOGY, 2022, 41 (02) : 557 - 566

← 1 2 3 4 5 →